TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases. Its lead product candidate, TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the VEGF pathway. The Company's other product candidates are TRC205, an anti-endoglin antibody that is in preclinical development for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. 
Type
Public
HQ
San Diego, US
Founded
2006
Size (employees)
26 (est)
TRACON Pharmaceuticals was founded in 2006 and is headquartered in San Diego, US
Report incorrect company information

Key People/Management at TRACON Pharmaceuticals

Charles P. Theuer

Charles P. Theuer

President and CEO

TRACON Pharmaceuticals Office Locations

TRACON Pharmaceuticals has an office in San Diego
San Diego, US (HQ)
4350 La Jolla Village Dr
Show all (1)
Report incorrect company information

TRACON Pharmaceuticals Financials and Metrics

TRACON Pharmaceuticals Financials

USD

Net income (FY, 2017)

(19.1 m)

EBIT (FY, 2017)

(18.2 m)

Market capitalization (23-Apr-2018)

46.2 m

Cash (31-Dec-2017)

29.5 m
TRACON Pharmaceuticals's current market capitalization is $46.2 m.
Annual
USDFY, 2015FY, 2016FY, 2017

General and administrative expense

5.7 m7.9 m7.6 m

R&D expense

25.7 m21.6 m19.4 m

Operating expense total

31.4 m29.4 m27 m

EBIT

(23.5 m)(26 m)(18.2 m)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

General and administrative expense

1.5 m1.5 m2 m2 m1.9 m2 m2.1 m

R&D expense

5.4 m5.9 m5.5 m6.8 m4.5 m5.6 m4.9 m

Operating expense total

6.9 m7.4 m7.5 m8.8 m6.4 m7.5 m7 m

EBIT

2.7 m(6.2 m)(6.3 m)(8 m)(5.6 m)(6.9 m)(6.3 m)
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

41.4 m35.7 m29.5 m

Accounts Receivable

9.4 m

Inventories

8 m

Current Assets

53.3 m45.6 m36.1 m
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

47.2 m43.3 m34 m29.6 m32.2 m26 m

Current Assets

59.9 m46.8 m37.7 m36.5 m37.8 m32.8 m

PP&E

141 k152 k128 k106 k75 k78 k

Total Assets

60 m47 m37.9 m36.6 m37.9 m32.9 m
Annual
USDFY, 2015FY, 2016FY, 2017

Net Income

(24.4 m)(27 m)(19.1 m)

Depreciation and Amortization

94 k48 k

Accounts Payable

(2.2 m)776 k

Cash From Operating Activities

(27.2 m)(13.2 m)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(2.9 m)(6.4 m)(6.5 m)(8.3 m)(5.9 m)(7.1 m)

Accounts Payable

3.5 m6.1 m7 m8.6 m6.6 m6.7 m5.7 m
USDY, 2017

Financial Leverage

2.1 x
Show all financial metrics
Report incorrect company information